On Thursday 31st October 2024, Syros Pharmaceuticals (NASDAQ: SYRS) will be releasing its third quarter financial results. This much awaited announcement will be made before market open.
Based on the predictions of financial experts on Wall Street, the company is expected to reveal an anticipated $0.72 loss per share for the quarter. Additionally, the firm is poised to disclose a total revenue of $0.45 million for the quarter.
Looking back at the corresponding quarter from the previous year, the company's earnings report revealed a per-share loss of $1.43. This notable figure was attributed to the company's total revenue, which settled at an impressive $3.76 million during that specific quarter.
The company's yearly performance has been analyzed by Wall Street analysts, who have projected a total revenue of $0.87 million. Moreover, they anticipate the company to disclose loss of $2.16 per share for the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.59 | +54.6% | 0.00 M | -100.0% |
| Q1 2024 | $-0.10 | +88.2% | 0.00 M | -100.0% |
| Q4 2023 | $-2.18 | -1,182.4% | 0.39 M | -151.3% |
| Q3 2023 | $-1.43 | +55.5% | 3.76 M | -3.3% |
| Q2 2023 | $-1.30 | +75.9% | 2.83 M | -54.9% |
| *Growth on year-over-year basis | ||||
The business has scheduled a conference call on 31st October 2024 at 08:30 AM eastern time to discuss Q3 financial results.
Syros Pharmaceuticals (SYRS) experienced a trading range of $2.03 to $2.77, along with a total volume of 1.36 million shares during the day. The stock concluded Tuesday's regular trading session at $2.53, showing an upturn of 19.91 percent.
